Even after anti-androgen therapy, docetaxel remains useful in prostate cancer

(University of Colorado Anschutz Medical Campus) A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent reduction in prostate specific antigen (PSA), demonstrating the activity of this drug sequencing.

http://www.eurekalert.org/pub_releases/2016-01/uoca-eaa011016.php

Source: EurekAlert! - Cancer - January 10, 2016 Category: Cancer & Oncology Source Type: news